Zacks Initiates Coverage of RYTHM With Underperform Recommendation
Find out why Zacks issues an "Underperform" rating on RYM, being the first on Wall Street to initiate coverage on the stock. Explore how mounting debt, persistent losses and legal disputes cloud the outlook despite a pivot to brand-led, capital-light operations.
Zacks·1d ago
More News
Why Did RYTHM (RYM) Stock Jump Over 23% Overnight?
RYTHM Inc. shares jumped 23.3% after hours following strong Q3 revenue growth and nationwide THC beverage expansion.read more...
Benzinga·17d ago
Cannabis Stocks To Research - November 10th
Tilray Brands, Canopy Growth, SHF, Aurora Cannabis, SNDL, Cronos Group, and RYTHM are the seven Cannabis stocks to watch today, according to MarketBeat's stock screener tool. Cannabis stocks are...
MarketBeat·18d ago
RYTHM (NASDAQ:RYM) Posts Earnings Results
RYTHM (NASDAQ:RYM - Get Free Report) issued its earnings results on Friday. The company reported ($5.31) earnings per share (EPS) for the quarter. The company had revenue of $4.04 million during the...
MarketBeat·20d ago
Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million
Key PointsRythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, recently exercised and sold some stock options...